Literature DB >> 2540242

Active Epstein-Barr virus infection in post-viral fatigue syndrome.

N A Hotchin1, R Read, D G Smith, D H Crawford.   

Abstract

Serological evidence of active infection with Epstein-Barr virus (EBV) was found in 25 of 124 patients (20%) with the post-viral fatigue syndrome (PVFS). In another study on the same group of patients around 50% were found to have evidence of chronic enterovirus infection. No overlap was found between those patients with enterovirus infection and those with active EBV infection. We suggest that there are multiple causes of PVFS and that, in the absence of coexisting immunosuppressive disease which may itself reactivate the virus, EBV may be the aetiological agent in a predominantly female subgroup of patients with PVFS. Furthermore, the disease process in this subgroup may be immunopathological in nature.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2540242     DOI: 10.1016/s0163-4453(89)91150-x

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  11 in total

1.  Myalgic encephalomyelitis--a persistent enteroviral infection?

Authors:  E G Dowsett; A M Ramsay; R A McCartney; E J Bell
Journal:  Postgrad Med J       Date:  1990-07       Impact factor: 2.401

Review 2.  The Putative Role of Viruses, Bacteria, and Chronic Fungal Biotoxin Exposure in the Genesis of Intractable Fatigue Accompanied by Cognitive and Physical Disability.

Authors:  Gerwyn Morris; Michael Berk; Ken Walder; Michael Maes
Journal:  Mol Neurobiol       Date:  2015-06-17       Impact factor: 5.590

3.  Prevalence and Predictors of Persistent Symptoms After Clearance of SARS-CoV-2 Infection: A Multicenter Study from Egypt.

Authors:  Marwa Khalaf; Mohamed Alboraie; Muhammad Abdel-Gawad; Mohamed Abdelmalek; Ahmed Abu-Elfatth; Walaa Abdelhamed; Mariam Zaghloul; Rabab ElDeeb; Doaa Abdeltwab; Mohamed Abdelghani; Fathiya El-Raey; Hani Aboalam; Azza Badry; Mina Tharwat; Shima Afify; Doaa Elwazzan; Ahmed Shawkat Abdelmohsen; Hayam Fathy; Shaker Wagih Shaltout; Helal F Hetta; Shamardan E Bazeed
Journal:  Infect Drug Resist       Date:  2022-05-20       Impact factor: 4.177

Review 4.  What SARS-CoV-2 does to our brains.

Authors:  Tom Aschman; Ronja Mothes; Frank L Heppner; Helena Radbruch
Journal:  Immunity       Date:  2022-06-20       Impact factor: 43.474

5.  Biochemical and muscle studies in patients with acute onset post-viral fatigue syndrome.

Authors:  V R Preedy; D G Smith; J R Salisbury; T J Peters
Journal:  J Clin Pathol       Date:  1993-08       Impact factor: 3.411

6.  Evaluation of 3-month follow-up of patients with postacute COVID-19 syndrome.

Authors:  Buğra Kerget; Eda Çelik; Ferhan Kerget; Alperen Aksakal; Elif Yılmazel Uçar; Ömer Araz; Metin Akgün
Journal:  J Med Virol       Date:  2022-01-18       Impact factor: 20.693

7.  Frequent neurocognitive deficits after recovery from mild COVID-19.

Authors:  Marcel S Woo; Jakob Malsy; Jana Pöttgen; Susan Seddiq Zai; Friederike Ufer; Alexandros Hadjilaou; Stefan Schmiedel; Marylyn M Addo; Christian Gerloff; Christoph Heesen; Julian Schulze Zur Wiesch; Manuel A Friese
Journal:  Brain Commun       Date:  2020-11-23

8.  Analysis of the tumorigenic potential of common marmoset lymphoblastoid cells expressing a constitutively activated c-myc gene.

Authors:  N A Hotchin; N Wedderburn; I Roberts; J A Thomas; J A Bungey; B Naylor; D H Crawford
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

9.  Post-COVID-19 chronic symptoms: a postinfectious entity?

Authors:  Benjamin Davido; Sophie Seang; Roland Tubiana; Pierre de Truchis
Journal:  Clin Microbiol Infect       Date:  2020-07-23       Impact factor: 13.310

10.  Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19.

Authors:  Jonas F Ludvigsson
Journal:  Acta Paediatr       Date:  2020-12-03       Impact factor: 4.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.